Proteomic Changes in Patients With Myasthenia Gravis and Ravulizumab
Proteomic Changes in Patients With Myasthenia Gravis and Ravulizumab
Not yet recruiting · NCT07337395 · Registry updated 2026-01-13Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Proteomic Changes in Patients With Myasthenia Gravis and Ravulizumab | Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome | Not yet recruiting | Not stated | 2026-01-13 | NCT07337395 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Alexion Pharmaceuticals, Inc. | 48 |
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 491 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Fondazione Policlinico Universitario A. Gemelli IRCCS | Roma | Italy | 26 |